The current study designed in silico investigations upon the phloridzin metabolic series to estimate their potentiality to impact three molecular targets concerned with tumor initiation and tumor progress in humans: B-cell lymphoma protein (Bcl-2), human tankyrase 1 (TNKS1) and cyclooxygenase 2 (COX-2), respectively. The gene discussed is TNKS; the disease is neoplasm.